Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-β, eotaxin, and stem cell factor and their receptors in allergic rhinitis

Salib, Rami J.; Sanjiv, Kumar; Wilson, Susan J.; Howarth, Peter H.

doi:10.1016/j.jaci.2004.07.010

Cited by 41 publications

(45 citation statements)

References 14 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We could well speculate that it also happens at the nasal mucosa, and the CTA1-DD molecule may directly penetrate the barrier as a result of the increased epithelial permeability. Furthermore, it is also reported that mast cells, driven by the chemotactic response as a result of allergic inflammation, migrate from the nasal submucosa to the epithelium in rhinitic patients (43). Therefore, one more possibility is that mast cells upon activation may accumulate in the nasal epithelium where they may have direct contact with the CTA1-DD/IgG complexes instilled at that site.…”

Section: Discussionmentioning

confidence: 99%

Mast Cells Contribute to the Mucosal Adjuvant Effect of CTA1–DD after IgG-Complex Formation

Fang

Larsson

Mattsson

et al. 2010

The Journal of Immunology

View full text Add to dashboard Cite

Mast cell activation is one of the most dramatic immune-mediated responses the body can encounter. In the worst scenario (i.e., anaphylaxis), this response is fatal. However, the importance of mast cells as initiators and effectors of both innate and adaptive immunity in healthy individuals has recently been appreciated. It was reported that mast cell activation can be used as an adjuvant to promote Ag-specific humoral immune responses upon vaccination. In this study, we have used a clinically relevant mucosal adjuvant, cholera toxin A1 subunit (CTA1)–DD, which is a fusion protein composed of CTA1, the ADP-ribosylating part of cholera toxin, and DD, two Ig-binding domains derived from Staphylococcus aureus protein A. CTA1–DD in combination with polyclonal IgG induced degranulation and production of TNF-α from mouse mast cells. Furthermore, CTA1–DD and polyclonal IgG complex induced mast cell degranulation in mouse skin tissue and nasal mucosa. We also found that intranasal immunization with hapten (4-hydroxy-3-nitrophenyl) acetyl (NP) coupled to chicken gammaglobulin admixed with CTA1–DD complexed with polyclonal IgG greatly enhanced serum IgG anti-NP Ab responses and stimulated higher numbers of NP-specific plasma cells in the bone marrow as compared with that observed in mice immunized with NP-chicken gammaglobulin with CTA1–DD alone. This CTA1–DD/IgG complex-mediated enhancement was mast cell dependent because it was absent in mast cell-deficient KitW-sh/W-sh mice. In conclusion, our data suggest that a clinically relevant adjuvant, CTA1–DD, exerts additional augmenting effects through activation of mucosal mast cells, clearly demonstrating that mast cells could be further exploited for improving the efficacy of mucosal vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%

Mast Cells Contribute to the Mucosal Adjuvant Effect of CTA1–DD after IgG-Complex Formation

Fang

Larsson

Mattsson

et al. 2010

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…To address this need, immunohistochemical analysis of the expression of mast cell chemoattractants and their receptors was made in nasal biopsies from symptomatic atopic patients with perennial and seasonal allergic rhinitis. 18 Mast cells were significantly increased in the epithelium of both rhinitis groups. Immunoreactivity for TGF-b1, TGF-b2, and TGF-b3 was observed, predominantly localized to the superficial columnar epithelial cells.…”

Section: Allergic Rhinitismentioning

confidence: 88%

Advances in upper airway diseases and allergen immunotherapy

Nelson

2005

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Evidence of an increased prevalence of rhinitis in patients with asthma, and asthma in patients with rhinitis, supports the 1 airway concept. However, there are basic differences between the upper and lower airways, such as the virtual absence of remodeling in the nose compared with the bronchi, despite the presence of similar inflammation. Etiologic factors in chronic rhinosinusitis (CRS) attract increasing interest. Peripheral blood monocytes from patients with CRS release IL-4, IL-13, and IFN-gamma on stimulation with fungal antigens, especially those from Alternaria. This is not seen with cells from normal controls. However, a double-blind trial of intranasal amphotericin in CRS was negative. Evidence continues to accumulate of the pivotal role of regulatory T-lymphocytes secretion of IL-10 in the response to allergen immunotherapy. In patients with asthma and house dust mite allergy who are receiving appropriate pharmacotherapy and have instituted environmental controls, house dust mite immunotherapy provides marginal additional benefits in asthma control. Immunotherapy with cat dander extract at a maintenance dose containing 15 microg Fel d 1 produces a more consistent immunologic response than with maintenance doses containing 3.0 microg, whereas doses containing only 0.6 microg are no more effective than placebo. Sublingual immunotherapy for seasonal grass allergy can be safely administered by general practitioners, but symptom relief begins only in the second season of therapy. Sublingual immunotherapy for seasonal grass allergy in children reduced symptoms and onset of new asthma symptoms but, again, beginning only in the second year of treatment. A course of 6 weekly injections of ragweed Amb a 1 bound to cytosine phosphorothionate guanosine containing DNA produced a shift from T H 2 to T H 1 cytokine release both in peripheral blood cells and in the nose after allergen challenge. No symptom improvement was seen the first year, but symptoms were reduced the second year without further treatment.

show abstract

“…Apart from DNAH5 disorders, mutations of DNAI1, DNALI1, and DNAH9 have mostly been established as the characteristics associated with primary ciliary dyskinesia [19]. Marked suppression of DNAI1 expression was also reportedly induced by upregulation of transforming growth factor beta-1, which has been observed in patients with perennial and seasonal AR [2, 20]. Notably, the absence of DNALI1 protein frequently coexisted with the absence of DNAH5 protein in patients with primary ciliary dyskinesia [19].…”

Section: Discussionmentioning

confidence: 99%

Downregulation and Aberrant Localization of Forkhead Box J1 in Allergic Nasal Mucosa

Peng

Chen

Guan

et al. 2018

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Forkhead box J1 (FOXJ1) plays pivotal roles in motile cilia formation. However, it remains unclear whether abnormal expression or localization of FOXJ1 in nasal mucosa tissues is associated with allergic rhinitis (AR), in which impaired mucociliary clearance is implicated. Objective: We sought to investigate the expression and localization of FOXJ1 in inferior turbinate from patients with AR and controls. Methods: We assayed mRNA levels of FOXJ1, DNAI1, DNALI1, and DNAH9 by using whole-genome expression array and quantitative real-time polymerase chain reaction. We elucidated the localization of FOXJ1 by using immunofluorescence assays in paraffin sections and primary single cells. Four patterns of FOXJ1 localization (normal, N; intermediate, I; mislocalization, M; absence, A) were defined. We developed a semiquantitative scoring system to elucidate their localization in 5 areas per paraffin section, with individual sections being assigned a score between 0 and 2. Results: The mRNA levels of FOXJ1, DNAI1, DNALI1, and DNAH9 were significantly reduced in patients with AR compared with controls (all p < 0.05). The median (1st and 3rd quartile) of the FOXJ1 score was 0.4 (0.0 and 0.85) in patients with AR, and 0.2 (0.0 and 0.4) in controls (p < 0.05). For primary cytospin samples, the mean percentages of FOXJ1 localization patterns N, I, M, and A were 46.7, 10.0, 30.0, and 26.7% in patients with AR, and 82.5, 5.0, 5.0, and 7.5% in controls, respectively (p < 0.05). Conclusion: Downregulation and aberrant localization of FOXJ1 may be crucial characteristics of the allergic nasal mucosa.

show abstract

Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-β, eotaxin, and stem cell factor and their receptors in allergic rhinitis

Cited by 41 publications

References 14 publications

Mast Cells Contribute to the Mucosal Adjuvant Effect of CTA1–DD after IgG-Complex Formation

Mast Cells Contribute to the Mucosal Adjuvant Effect of CTA1–DD after IgG-Complex Formation

Advances in upper airway diseases and allergen immunotherapy

Downregulation and Aberrant Localization of Forkhead Box J1 in Allergic Nasal Mucosa

Contact Info

Product

Resources

About